ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Endo Is Second Bidder For Salix

by Michael McCoy
March 16, 2015 | APPEARED IN VOLUME 93, ISSUE 11

Seeking to best an earlier deal, Endo International has offered to acquire Salix Pharmaceuticals for $175.00 per share in cash and stock. Last month, Salix, a specialist in gastrointestinal treatments, agreed to be acquired by Valeant Pharmaceuticals for $158.00 per share, or about $14 billion including debt. Valeant says it stands by its all-cash deal, “which delivers immediate and certain value to Salix shareholders.” Salix says it will review the new offer.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment